Search

712 Result(s)
Sort by

Our partners university of georgia

Our partners university of georgia

We're partnering with the University of Georgia to address unmet needs and find solutions to some of the biggest challenges in animal health.
Code of Conduct

Code of Conduct

Our Code of Conduct sets the ethical standards that guides all our business activities. It´s about all of us. Each individual plays a vital role in bringing the Code of Conduct to live.
A professional family

A professional family

We believe that great teams are made up of people who are happy, fulfilled and have a sense of purpose. Flexibility and work/life balance are highly valued.
Risk of parasites in dogs

Risk of parasites in dogs

With our Parassess free online tool checker, you can assess the local parasite risks for your dog so you can protect them better.
Sore Mouth or Throat

Sore Mouth or Throat

Discover tips on how to take care of a sore mouth or throat from Taking Cancer On Through Flavour
CHMP_opinion_nintedanib_ILD_PF

CHMP_opinion_nintedanib_ILD_PF

Nintedanib received a CHMP positive opinion for the treatment of patients with other chronic fibrosing ILDs with a progressive phenotype beyond IPF
The impact of A Life in a Day of a patient

The impact of A Life in a Day of a patient

A Life in a Day disease simulations are opening our eyes to the patient experience, exposing a surprising knowledge gap and driving change.
Small Cell Lung Cancer

Small Cell Lung Cancer

Discover more about small cell lung cancer, including its symptoms and treatment options.
Dedifferentiated liposarcoma (DDLPS)

Dedifferentiated liposarcoma (DDLPS)

An aggressive subtype of a category of cancers called soft tissue sarcoma (STS). DDLPS has a poor prognosis and limited treatment options.
Non-small cell lung cancer

Non-small cell lung cancer

Discover more about non-small cell lung cancer, including its symptoms and treatment options.
Results for Jardiance EMPACT-MI phase III trial

Results for Jardiance EMPACT-MI phase III trial

Results announced from EMPACT-MI phase III trial investigating the effect of Jardiance® (empagliflozin) on risk of heart failure hospitalization and death in adults following a heart attack
EC_approval_nintedanib_ILD_PF

EC_approval_nintedanib_ILD_PF

European Commission approves nintedanib for the treatment of patients with other chronic fibrosing ILDs with a progressive phenotype beyond IPF
“My ultimate goal is to cure cancer”

“My ultimate goal is to cure cancer”

Norbert Kraut, our Global Head of Cancer Research, shares how we are advancing science to bring new treatment options for people living with cancer.
empa-reg-outcome-recurrent-events

empa-reg-outcome-recurrent-events

EMPA-REG OUTCOME® analysis: Empagliflozin reduced risk of first plus recurrent cardiovascular events in adults with type 2 diabetes and CV disease